Abbreviations: AOR, adjusted odds ratio; ART, abbott realtime; DAA, direct-acting antiviral agents; DAQ>42, detectable above quantification with an HCV RNA level ≤42 IU/mL; DAQ≤42, detectable above quantification with an HCV RNA level ≤42 IU/mL; DAQ, detected above quantification; DBQ, detectable below quantification; DBQ, detected below quantification; LDV, ledipasvir; LOQ, limit of quantification; PEG, pegylated interferon; PrOD, Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir; RIBA, ribavirin; SOF, sofosbuvir; SVR, sustained virologic response; VA, Veterans Affairs; W4VL, week 4 viral load; W4VL, week 4 viral load (the HCV RNA viral load 4 weeks after initiation of antiviral treatment). 
trials of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin, the proportion of patients with quantifiable HCV RNA level at week 4 of treatment, which was defined as a level ≥25 IU/mL, was well below 1%, [1] [2] [3] suggesting that little information could be gained by this test as it was almost uniformly negative. However, the joint guidelines from American Association for the Study of Liver Diseases/Infectious Diseases Society of America recommend measuring HCV RNA viral load 4 weeks after initiating antiviral treatment. 4 In practice, HCV RNA viral loads are frequently measured at 4-week intervals during antiviral treatment, partly as a way to assess compliance.
In a study of real-world clinical practice, week 4 viral load (W4VL) was found to be detectable in approximately 24% of treatment-naïve, genotype 1-infected patients treated with LDV/SOF±ribavirin, 5 in stark contrast to the reports of randomized controlled trials. 1, 2 This study also showed a correlation between W4VL and sustained virologic response (SVR). In two other studies, week 4 viral load was correlated to SVR among patients with genotype 3 HCV infection treated with daclatasvir/sofosbuvir 6 or sofosbuvir/ribavirin.
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Assuming that the W4VL does predict SVR, it is important to determine the magnitude of this association, and whether it should influence treatment decisions. For example, should patients with a detectable W4VL undergo longer duration of treatment in an effort to improve their SVR? Or, conversely, should patients with a detectable and quantifiable W4VL above a certain level discontinue treatment on the grounds of futility?
Our aim was to determine the extent to which W4VL predicts SVR for different genotypes, treatment regimens and clinically relevant patient subgroups treated in a real-world clinical setting within the Veterans Affairs (VA) healthcare system. We also aimed to determine whether treating patients with genotype 1 HCV who are now considered eligible for 8 weeks of ledipasvir/sofosbuvir monotherapy with 12 weeks instead of 8 improves SVR in patients with detectable or quantifiable W4VL.
| METHODS

| Data source
We extracted data from the VA Corporate Data Warehouse, a national repository of data obtained from the VA electronic medical records. 8 Data extracted included all pharmacy prescriptions, demographics, inpatient and outpatient visits, problem lists, procedures, vital signs, diagnostic tests and laboratory tests. Data extended back to 10/01/1999 to determine whether patients had received prior HCV treatments and extended forward to 04/15/2016 to allow for completion of treatments and ascertainment of SVR.
| Study population and antiviral regimens
Of 24 089 HCV antiviral regimens initiated in the VA nationally from 01/01/2014 (the month after SOF was approved by the FDA) to 06/30/2015, we excluded 2585 regimens that were no longer used or recommended by the time we analysed our data (eg SOF+pegylated interferon (PEG)/ribavirin (RIBA) and SOF+RIBA for genotype 1-infected patients and all PEG/RIBA regimens). We additionally excluded 409 "duplicate" regimens, in which the same patient appeared to have received one very short "regimen" (eg, 14-day regimen) followed at a later date by a longer course of the same regimen (these short, "duplicate" regimens were most likely erroneous or postponed prescriptions) leaving 21 095 patients in the current analysis, all of whom were treated with the direct antiviral agents SOF, simeprevir (SMV)+SOF, ledipasvir/sofosbuvir (LDV/SOF) or Paritaprevir/ Ritonavir/Ombitasvir/Dasabuvir (PrOD) with or without ribavirin. with SVR ascertained based on viral load >12 weeks after the end of treatment in SOF-treated patients. 21 Duration of therapy and end of treatment were defined by the total duration of DAA prescriptions filled. 
| Baseline characteristics
| Week 4 viral load
| Characteristics associated with week 4 viral load
Baseline characteristics that were associated with high DAQ rate (≥15%) were as follows: high baseline HCV viral load (>6 million IU/ mL), HIV co-infection, liver transplantation, cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, elevated serum bilirubin, elevated INR, elevated FIB-4 score, low serum albumin and low platelet count (Table S2) . Using multivariable analysis, independent predictors of a T A B L E 1 Categories of week 4 viral load in patients undergoing DAA-based antiviral treatment, subdivided by type of assay
Week-4 viral load
All patients (N=21 095)
Type of HCV RNA assay
Abbott assay LOQ=12 IU/mL N=4946
Roche assay LOQ=15 IU/mL N=15 730
Other assays N=419 All N=21 095 After adjusting for all baseline characteristics listed in the legend of (Table 6 ). All P-values are for comparisons to the reference group (undetectable W4VL) in predicting SVR. N/A Not applicable. Most genotype 3-infected patients were treated with 24 wks of sofosbuvir and ribavirin.
| Association between week 4 viral load and SVR
| DISCUSSION
a AOR: adjusted odds ratio, by multivariable logistic regression modelling including week 4 viral load category, type of HCV RNA assay, duration of treatment, race/ethnicity, age, genotype/subgenotype, regimen, gender, baseline HCV viral load, platelet count, serum bilirubin level, serum albumin level, alcohol use disorder, diabetes, cirrhosis, decompensated cirrhosis, HCC, liver transplantation and prior treatment.
T A B L E 4 (Continued)
The proportion of all available W4VLs that were DBQ (40.4% for Abbott and 47.4% for Roche assays) or DAQ (36.2% for Abbott and 10.5% for Roche assays) was much greater than the DBQ rate (18.8%-19.1%) and the DAQ rate (0.2%-0.7%) reported in the ION1-3 randomized controlled trials. [1] [2] [3] Randomized trials may select for lower risk/more compliant patients than real-world patients, so their viral loads could fall more quickly. Perhaps more importantly, these three ION randomized trials used a Roche assay (COBAS TaqMan HCV Test, version 2.0, for use with the High Pure System) that is less sensitive for detecting extremely low levels of virus, with a LOQ of 25 IU/mL, as compared to LOQ of 12 or 15 IU/mL in our study. Subsequent studies reported that W4VLs were undetectable in only 10%-14% using the Abbot assay and 51%-55% using the Roche assay among genotype 1-infected patients treated with SMV+SOF±RIBA or daclatasvir+SOF,
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which is closer to our finding of 23.5% (Abbott) and 39.4% (Roche) undetectable W4VL. Taken together with these studies, our findings suggest that DAQ and DBQ at W4VL is a common occurrence that merits further study, and that it is much more common with the Abbott than with the Roche assays, as demonstrated by two other recent studies. 23, 24 Whether the higher positivity rate of the Abbott relative to the Roche assay is due to a greater true-positive rate or a greater false-positive rate or both remains to be determined.
Our results demonstrate that W4VL is a very strong, independent predictor of SVR, irrespective of assay used and among almost all clinically relevant subgroups of patients. 
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Although DAQ>42 was very strongly associated with lower likelihood of SVR, the absolute SVR rate (86.2%) was still very high in these patients (Table 3) . Therefore, in agreement with other studies, 6,30 our results suggest that antiviral treatment should not be discontinued early based on a W4VL that is DAQ>42. We do advocate for checking the W4VL, however, to document compliance early in these very expensive treatment courses.
One limitation of our study is that W4VL was missing in a significant proportion (26.2%) of patients. Although the absence of W4VL data clearly identified patients with higher likelihood of early discontinuation and lower likelihood of SVR, it is unlikely that this systematically biased our comparisons between different categories of W4VL among patients with available data. Also, our study is limited by missing SVR data; however, the rate of missing SVR data was very low among patients with available W4VL and was very similar for undetectable, DBQ, DAQ≤45 and DAQ>45 such that it is unlikely that any systematic bias was introduced in the association between W4VL and SVR rates. We did not have direct documentation of the HCV RNA assay system (Abbott vs Roche); instead we extrapolated the assay from the reported lower limit of quantification. The striking differences in rates of DAQ that we found between the two assays suggest that we are categorizing them accurately. Another weakness of this study is its observational nature. A randomized trial would have been optimal to answer the question of whether patients with a W4VL that is DAQ benefit from extending treatment from 8 to 12 weeks, but such a trial is probably not feasible due to the very large sample size.
In conclusion, W4VL is detectable and even quantifiable a lot more frequently than what had been reported in clinical trials and a lot more commonly with Abbot than Roche assays. W4VL is a very robust predictor of SVR across almost all clinically subgroups. However, whether and how W4VL results should be used to influence treatment decisions requires further study.
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